#USA #Austin #RazorMetrics #Drug Access #Prescription Affordability

Rising Concerns Over Prescription Drug Costs in America

A recent study conducted by RazorMetrics sheds light on an increasingly pressing issue: prescription drug affordability. In their 2025 State of Drug Access report, it was revealed that almost 42% of Americans have been prescribed medications they simply cannot afford. This statistic stems from a nationwide survey that also uncovers the frustrations patients face regarding the cost of their medications.

With the rising inflation and surging demand for GLP-1 medications such as Ozempic and Wegovy, Americans are finding it harder to manage their healthcare expenses. As Dr. Siva Mohan, president and chief medical officer of RazorMetrics, points out, the data highlights that financial pressures are not just an inconvenience but a significant barrier, leading to serious health implications as many individuals struggle to access necessary prescriptions.

Key Findings

The report highlights several key findings that paint a bleak picture of prescription access:

• - 41.8% of respondents indicated they had been prescribed a drug they could not afford within the past year.
• - 84% experienced sticker shock for medications priced under $250, with nearly half of those deeming even medications under $100 as unaffordable.
• - A troubling 11.4% entirely stopped taking their prescribed medications due to prohibitive costs.
• - Faced with expensive prescriptions, 47.2% of respondents chose to contact their doctor as the first point of support, far surpassing those who reached out to insurers or sought discounts.
• - 53.1% found the pricing structure for medications confusing, illuminating a major communication gap in health care.
• - Surprisingly, only 18.3% of Americans are aware of what a biosimilar is, despite their growing presence in the market as a cost-saving option.

These statistics indicate that more Americans are grappling with the reality of drug prices affecting their health choices, making it a public concern. The majority of Americans are looking towards their healthcare providers for solutions rather than relying on apps or insurance services.

Consumer Frustration

One of the most significant pain points highlighted in the survey is the struggle to find affordable medication. Nearly half of the survey participants expressed that they found healthcare apps designed to aid medication access to be overwhelming or inconsistent, which adds another layer of complexity to an already complicated issue.

Despite these frustrations, there remains a willingness to explore lower-cost medication alternatives. A solid 90% of respondents stated they would be amenable to their physician recommending cheaper medication options, while 85.5% expressed the desire for doctors to prioritize cost-effective prescriptions when clinically viable.

Prescribers as Cost Navigators

The findings emphasize a shift in the role of healthcare providers. Ryan Czado, chief pharmacy officer at RazorMetrics, notes that physicians are increasingly seen as cost navigators. The data shows that patients are seeking affordability solutions from their doctors, highlighting a growing expectation for prescribers to actively engage in discussions around medication costs.

To address these challenges, smart automation can pave the way for improved affordability without disrupting the workflows that healthcare providers currently rely on. There is a critical need for tools that empower prescribers to surface cost-saving opportunities seamlessly, helping both patients and healthcare systems navigate the complexities of prescription drug pricing.

Conclusion

As the demand for high-cost medications continues to rise, the issue of affordability is firmly rooted in the healthcare conversation for 2025 and beyond. RazorMetrics' report not only captures the current crisis but also outlines the necessary steps that prescribers and plan sponsors must take to facilitate better access and affordability for patients.

For those interested in diving deeper into the data, the full report is available, offering further insights into the state of drug access and potential pathways towards resolving these systemic issues.